Hints and tips:
Related Special Reports
...A Humira biosimilar from Teva Pharmaceuticals working with Alvotech earlier this year became the first drug that the US Food and Drug Administration granted interchangeable status, which lets pharmacists...
...BioNTech [also] doesn’t have any other products so it’s a lot of cash to have to pay,” said Christopher Sharp, an IP lawyer at Pinsent Masons....
...Teresa Graham, chief of Roche’s pharmaceutical division, said more patients suffered from diseases of the immune system than from cancer, and the current drugs did not serve them well....
...In May, the Pharmaceutical Supply Chain Initiative, a lobby set up by large pharmaceutical companies, said its members should stop sourcing blood from the two Asian horseshoe crab species most at risk....
...He accepted that the threats of IP theft and being front-run were “valid concerns” but believed in practice “it hasn’t been borne out. It’s not a real risk, it’s a theoretical risk....
...Spirax-Sarco, a top engineering group, and AstraZeneca, the pharmaceuticals producer, sit at more than £90 for a single share....
...The transaction left GSK and Pfizer holding 13.5 per cent and 32 per cent of the shares, respectively....
...So, of course it created the densest patent thicket ever,” said Brian O’Reilly, the founding partner of the law firm O’Reilly IP....
...It also generated excitement across the pharmaceutical industry, which is enticed by the prospect of selling medicines to the more than 50mn people worldwide who suffer from the disease....
...PMI chief executive Jacek Olczak told the Financial Times that Vectura’s sales had suffered because of the reluctance of pharmaceutical partners to work with the company....
...Some analysts say it is Illumina rather than Grail that faces the biggest near-term risks given the terms of a holding agreement imposed by EU regulators on the company before they issue a final divestment...
...Intangible assets, such as trademarks, are highly valuable to the business, which uses this automated system to track and enforce its IP....
...But they warn that the ruling casts a shadow over the company as it seeks to remodel itself as an innovator in the pharmaceutical and medical devices sectors....
...A version of this article was first published by Nikkei Asia on September 26 2022. ©2022 Nikkei Inc. All rights reserved....
...Oxfam is lobbying to create a more equal distribution of Covid-19 vaccines, arguing that not sharing the IP and technical knowhow creates reputational risks and could slow the end of the pandemic....
...Meanwhile, real estate developers and investors have latched on to life sciences as the rise of working from home threatens financial returns from their office holdings....
...Twitter’s board plans to share the “fire hose” of publicly available data about tweets, but it will not include crucial private user information, such as IP addresses. 4....
...Tishman Speyer, one of New York’s largest commercial property developers, had previously secured pharmaceuticals company Pfizer as its anchor tenant for the Spiral....
...The measures represent “the most crucial pivot since Beijing significantly tightened financing of the property sector,” economists at Nomura Holdings Inc. wrote Monday in a note....
...The following day, Cohen disclosed plans to also sell his holding of roughly 12 per cent, and the shares plunged. By the end of the week they were worth just $11....
...Berkshire’s securities filing on Monday showed that it continued to sell down investments in a handful of pharmaceutical companies in the final months of 2021....
...Ngozi Okonjo-Iweala, WTO director-general, said on Thursday that the IP talks were “stuck”....
...Michael Sklar, develops “nonstandard trial designs”, which seems to basically use maths to speed up the process of developing pharmaceutical studies....
...“Pharmaceutical companies have a duty to do their utmost on this but unfortunately we see that they are lagging behind....
...It is the first time the US pharmaceutical company has agreed to share the technology behind a Covid-19 medical product, in contrast to its refusal to license its vaccine to generic manufacturers....
International Edition